Angelica gigas Nakai for Health & Longevity

Evidence Review created on 09/06/2026 using AI4L / Opus 5

Also known as: Korean Angelica, Korean Dang-Gui, Cham-Dang-Gui, Angelicae Gigantis Radix, Giant Angelica

Motivation

Angelica gigas Nakai — Korean angelica, or cham-dang-gui — is a tall purple-flowered plant of the carrot family whose thick root has been dried, sliced and boiled into medicinal teas in Korea for centuries. The root is unusually rich in a family of sweet-smelling plant compounds that the Chinese and Japanese plants sharing the same trade name do not contain, and that chemical difference is what modern interest turns on.

Traditionally the root was given to women for menopausal complaints and to both sexes for pain, simmered in water rather than swallowed as a concentrate. Since the early 2000s it has been sold in North America and Europe as a capsule, and Korean regulators have cleared a standardized root extract as a functional food ingredient. Telling the plant apart from its look-alikes has become a research question in its own right.

This review examines what controlled human research, animal work and laboratory studies show about this root and its main compounds: what has been measured in people, what rests on animals alone, how the body handles the compounds after they are swallowed, and where product quality varies.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Angelica gigas

A dedicated botanical and pharmacological entry covering taxonomy, distribution, cultivation, traditional use and phytochemistry, useful for separating the species from the other plants sold as dang-gui.

Examine

Dong Quai

Examine’s dedicated page for this species, summarizing the hormonal, immune and anti-cancer signals and stating plainly that the evidence is preliminary and not yet sufficient to support specific use.

ConsumerLab

ConsumerLab has not published a product review, clinical update or dedicated article on Angelica gigas Nakai; no ConsumerLab article on this intervention exists.

Systematic Reviews

Pooled evidence in which Angelica gigas Nakai is a named, analyzed component.

Herbal therapeutics for female infertility: A systematic review and meta-analysis - Hyun et al., 2024

Pooled 18 trials in 2,662 women; Angelica gigas Nakai was the second most-used single herb and pregnancy rates rose versus placebo.

Trade-off coverage: the pooled literature covers only the benefit side. No systematic review or meta-analysis exists on the harms, safety or drug-interaction burden of this intervention, nor on the opportunity cost of using it in place of conventional lipid-lowering or analgesic therapy, so the risk side of the trade-off is unrepresented in this section and is handled below from primary trials and toxicology studies.

Mechanism of Action

The dried root’s ethanol extract is dominated by two mirror-image pyranocoumarins, decursin and decursinol angelate, together with the coumarin glycoside nodakenin. In healthy adults given a standardized supplement, both parent compounds are stripped almost completely on first pass through the liver to a single metabolite, decursinol: peak blood levels were roughly 5, 48 and 2,480 nmol/L for decursin, decursinol angelate and decursinol respectively. Elimination half-life — the time for blood levels to halve — ran about 17–19 hours for the parents and 7 hours for decursinol. Conversion is catalyzed mainly by cytochrome P450 2C19 (CYP2C19, a liver enzyme that clears many medicines) and secondarily by CYP3A4 (another broad-spectrum drug-clearing liver enzyme), with carboxylesterase-2 (a decursin-splitting enzyme) contributing. In mice, parent compounds concentrate outside the liver while decursinol dominates blood and crosses the blood-brain barrier.

Decursinol inhibits acetylcholinesterase and produces pain relief through the central nervous system rather than through the cyclo-oxygenase enzymes that ordinary anti-inflammatory medicines block. The extract also activates AMPK (adenosine-monophosphate-activated protein kinase, a cellular fuel gauge) and SIRT1 (sirtuin 1, a protein that tunes how cells handle energy) signaling, suppressing fat synthesis, and blocks NF-κB (nuclear factor kappa B, a master switch for inflammatory genes).

Two mechanistic accounts compete. The larger cell-culture literature attributes activity to decursin and decursinol angelate directly; the pharmacokinetic camp argues those compounds barely reach tissue in people and that decursinol is the true actor, a reading supported by mouse tumor work where decursinol outperformed an equal molar dose of the parent pair.

Historical Context & Evolution

The root entered Korean medicine as cham-dang-gui, prescribed for “blood deficiency” states — anemia, painful or absent menstruation, poor circulation, convalescent weakness — usually simmered in water. Its original use was therefore gynecological and restorative, not preventive. Confusingly, three plants are sold under the dang-gui name: the Korean Pharmacopoeia lists Angelica gigas, the Chinese Pharmacopoeia lists Angelica sinensis, and the Japanese Pharmacopoeia lists Angelica acutiloba. Chemical fingerprinting shows they share almost no marker compounds — the Korean root is defined by decursin, decursinol angelate and nodakenin, the Chinese by ligustilide and ferulic acid.

Interest in health optimization grew out of Korean isolation chemistry in the 1990s and early 2000s. Coumarins from the root were shown to inhibit acetylcholinesterase and to reverse chemically induced amnesia in mice; separate work found dose-dependent pain relief across several animal pain models; and groups in Korea and the United States reported that decursin blocked androgen-receptor signaling in prostate cancer cells. Commercial extracts standardized on decursinol followed, marketed for pain and memory; a Korean-approved extract for blood triglycerides came later.

The picture then shifted rather than collapsed. Human pharmacokinetic studies from 2013 to 2015 showed the parent compounds are almost entirely converted before reaching tissue, so much of the cell-culture literature does not describe what circulates in a person. The response was not that the earlier findings were wrong but that attention moved to the metabolite, which retains analgesic, enzyme-inhibiting and anti-tumor activity in animals. What remains unsettled is whether repeated dosing changes that conversion.

Expected Benefits

High 🟩 🟩 🟩

Relief of Menopausal Symptoms (as Part of a Standardized Three-Herb Extract)

A standardized blend of Angelica gigas Nakai root with Cynanchum wilfordii and Phlomis umbrosa reduces hot flashes, insomnia, nervousness, fatigue and vaginal dryness. Placebo-controlled trials in North American and Iranian women, plus a combination trial adding gamma-aminobutyric acid (the brain’s calming messenger), agree on the direction of effect, scored by the Kupperman Menopause Index, a validated eleven-symptom questionnaire. Receptor assays indicate the blend is not estrogenic. The evidence covers the mixture, so the share attributable to this root alone is unknown, and every trial was industry-sponsored.

Magnitude: The Kupperman Menopause Index fell from 29.5 to 11.3 over twelve weeks versus 29.2 to 23.7 on placebo (Chang et al.); in a separate twelve-week trial mild, moderate and severe hot flashes were each less frequent than placebo by week six (p<0.001, where p is the probability that a difference this large arose by chance) (Farzaneh et al.).

Medium 🟩 🟩

Lower Fasting Triglycerides

A twelve-week randomized, double-blind, placebo-controlled trial in 100 Korean adults with mildly raised triglycerides found that 200 mg per day of a standardized root extract lowered triglycerides, very-low-density lipoprotein cholesterol (the triglyceride-carrying lipoprotein) and the ratio of triglycerides to high-density lipoprotein (HDL) cholesterol, while total and low-density lipoprotein (LDL) cholesterol were unchanged. Rodent work attributes this to AMPK and SIRT1 signaling that suppresses fat synthesis and speeds fat burning. One trial only, funded by the extract’s manufacturer, in one ethnic group.

Magnitude: Triglycerides fell from 158.2 to 143.4 mg/dL while placebo rose from 159.4 to 179.4 mg/dL, and the triglyceride-to-HDL ratio moved from 3.23 to 2.87 versus 3.34 to 3.87 on placebo (Jung et al.).

Improved Lower Urinary Tract Symptoms (with Astragalus)

In men with benign prostatic hyperplasia (the age-related, non-cancerous prostate enlargement that obstructs urine flow), a twelve-week trial of a two-herb product combining this root with Astragalus membranaceus improved the International Prostate Symptom Score, a validated urinary symptom questionnaire, most clearly on incomplete emptying, and raised erectile-function scores. Prostate-specific antigen, testosterone, dihydrotestosterone, peak urinary flow and residual urine volume did not change, so symptom relief was not matched by objective flow measures. Single manufacturer-sponsored trial of a mixture.

Magnitude: The International Prostate Symptom Score fell 3.41 points versus 1.36 on placebo over twelve weeks (p=0.0219), and the erectile-function index rose 6.15 points versus a 2.58-point fall (p=0.0354) (Lee et al.).

Reduced Crow’s-Feet Wrinkles from Topical Root Extract

An eight-week randomized, split-face, double-blind trial applied a lotion containing 0.025% root extract to one side of the face and placebo to the other, measuring wrinkle roughness optically. Roughness and dermatologist-scored photodamage fell on the treated side and differed significantly from the placebo side. Topical, cosmetic and single-trial, with an industry-employed author group.

Magnitude: Total skin roughness fell 19.64 arbitrary units from a baseline of 151.38 after eight weeks, against no significant change on the placebo side (Kang et al.).

Low 🟩

Relief of Chronic Degenerative Joint Pain

Animal models show dose-dependent pain relief from the root extract and from decursinol, acting centrally rather than through the cyclo-oxygenase enzymes. The only human joint-pain study remains unpublished, sponsor-funded and reported through a supplement seller, so the human signal is uncontrolled by modern standards.

Magnitude: Pain scores improved in 68% of 40 adults taking 250 mg twice daily alongside physical therapy versus 15% on physical therapy alone over two weeks, in an unpublished clinic study; no peer-reviewed trial has measured this outcome.

Speculative 🟨

Memory and Cognitive Support

Root extract improves memory in mouse models of mild cognitive impairment, and root coumarins inhibit acetylcholinesterase. No human cognition trial has been published, so the basis is animal and mechanistic only.

Tumor Growth and Metastasis Inhibition

Ethanol extract and decursinol shrink prostate cancer grafts and lung spread in mice and block androgen-receptor signaling in cells. Human work is confined to safety and pharmacokinetic studies; no efficacy trial has reported.

Anti-Inflammatory and Immune Modulation

Decursinol angelate suppresses inflammatory signaling in macrophages and eases chemically induced colitis in mice. The basis is cell and animal work only; a small human immune-cell study has not published results.

Platelet Inhibition and Blood-Flow Support ⚠️ Conflicted

Decursin and decursinol angelate inhibit human platelet clumping in vitro as strongly as aspirin, and an extract cut clot-driven death in mice; no human circulation endpoint exists. Net reading: unproven in people.

Bone Preservation

Decursin blocks formation of bone-resorbing osteoclasts and reduced bone loss in mice, and root extract inhibits osteoclast formation in culture. No human bone-density or fracture data exist.

Female Fertility and Embryo Implantation

Decursinol raised implantation-related adhesion molecules and embryo-cell attachment in cultured human endometrial cells. The only pooled human evidence is for multi-herb formulas containing the root, so nothing isolates its contribution.

Anxiety and Sleep Effects

Decursin and decursinol angelate promote the enzyme that makes gamma-aminobutyric acid; a review of the animal literature reports anti-anxiety, sleep and anticonvulsant activity. No human trial has tested these endpoints.

Benefit-Modifying Factors

CYP2C19 genotype: In the human pharmacokinetic study, carriers of the ultrarapid CYP2C19 variant showed lower decursinol angelate exposure and poor-metabolizer carriers showed higher exposure, so genotype shifts how much parent compound survives absorption.
Baseline biomarker levels: The lipid trial enrolled only adults starting between 130 and 200 mg/dL of triglycerides. Nothing indicates benefit at already-optimal levels, and the effect scales with how far the starting value sits above target.
Sex-based differences: Men absorbed the parent pyranocoumarins faster and reached peak decursinol concentrations sooner than women in the single-dose human study. The menopause evidence is female-only; the urinary-symptom evidence is male-only.
Pre-existing health conditions: Documented benefit is confined to three states — mild hypertriglyceridemia (raised blood triglycerides), symptomatic prostate enlargement, and the menopausal transition. Outside these, no human outcome has been measured.
Age-related considerations: Both the urinary-symptom and menopause trials enrolled adults in their fifties and older, the range where benefit is best documented. Declining CYP2C19 activity and liver blood flow with age may raise parent-compound exposure, an untested prediction.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Gastrointestinal and Nonspecific Adverse Events

Across the published human trials the reported events were indigestion, bloating, epigastric discomfort, abdominal pain, dermatitis and rash, headache, dizziness and upper-respiratory infection. None was severe, none caused withdrawal, and in both trials the event rate did not differ significantly from placebo — in the urinary-symptom trial it was numerically lower on the active product. The pattern is consistent across two independent twelve-week trials in different populations, which is why it is graded here rather than lower.

Magnitude: 17 events among 50 people taking the extract versus 10 among 50 on placebo over twelve weeks in the lipid trial, and 3 events in 6.0% of treated men versus 7 events in 10.0% of controls in the urinary-symptom trial.

Medium 🟥 🟥

Transient Liver-Enzyme Elevation

Two of fifty participants on the extract in the lipid trial recorded liver-enzyme elevation as an adverse event, and in the urinary-symptom trial alanine and aspartate aminotransferase (liver enzymes released when liver cells are stressed) rose from baseline significantly more than in controls, though every value stayed inside the normal reference range and well below the three-fold threshold defining drug-induced liver injury. A 13-week rat study found no liver damage at any dose. Reversible and subclinical on current evidence.

Magnitude: 2 of 50 participants over twelve weeks in the lipid trial; group-level aminotransferase rises that stayed within the reference range in the urinary-symptom trial (p=0.0036 for aspartate aminotransferase, p<0.0001 for alanine aminotransferase).

Low 🟥

Drug-Interaction Potential Through Liver Enzyme Inhibition

Decursinol angelate irreversibly inactivates CYP2A6 (the liver enzyme clearing nicotine and coumarin), and both pyranocoumarins are handled by CYP2C19 and CYP3A4. Human genotype data confirm the pathway operates in people, but no clinical interaction study has been run, so the consequence is inferred rather than observed.

Magnitude: In human liver microsomes (liver enzyme preparations) the concentration halving CYP2A6 activity fell from above 20 μmol/L to 4.4 μmol/L after a 20-minute pre-incubation, the signature of irreversible inactivation (Yoo et al.); no human study has quantified a clinical consequence.

Speculative 🟨

Bleeding Risk from Platelet Inhibition ⚠️ Conflicted

Pyranocoumarins block human platelet clumping in vitro as potently as aspirin, yet extract-fed mice showed no gut bleeding and human trials reported none. Net reading: theoretical, not yet observed.

Photosensitivity from Furocoumarin Content

Pharmacopoeial analysis of a marketed Angelica gigas supplement detected psoralen, xanthotoxin and bergapten — furocoumarins that sensitize skin to ultraviolet light. No human photosensitivity case attributable to this herb has been reported.

Effects on Hormone-Sensitive Tissue

Decursinol behaves as an androgen-receptor agonist while decursin and its isomer act as antagonists or degraders of androgen and estrogen receptors (narrative review). The net direction in a person with hormone-sensitive disease is unknown.

Mycotoxin Contamination of Root Material

Field-drying and overloaded thermal drying let ochratoxigenic molds grow on the root, raising ochratoxin A — a kidney-toxic mold toxin — in finished material. No human exposure or outcome data exist for this herb.

Risk-Modifying Factors

CYP2C19 poor-metabolizer status: Carriers of two reduced-function CYP2C19 alleles clear decursinol angelate more slowly and reach higher parent-compound exposure, plausibly amplifying both effect and interaction risk.
Baseline biomarker levels: Adults starting with alanine or aspartate aminotransferase already at the upper reference limit have less headroom before the small, within-range rises seen in trials cross a clinically meaningful threshold.
Sex-based differences: Faster parent-compound absorption in men means higher early peaks. Women were the only sex studied for hormonal safety, so the absence of an estrogenic signal is female-derived and does not transfer to men.
Pre-existing health conditions: Liver disease, bleeding disorders, hormone-sensitive cancers and chronic kidney disease each intersect a documented or plausible signal — enzyme rises, platelet inhibition, receptor activity and mycotoxin exposure respectively.
Age-related considerations: Adults past 65 carry more concurrent medications, multiplying the enzyme-interaction surface, and reduced liver clearance, raising exposure. No trial has enrolled a dedicated older cohort.

Key Interactions & Contraindications

CYP2C19 substrates (clopidogrel, omeprazole, escitalopram, voriconazole): Caution; competition at the enzyme can raise substrate levels or, for the prodrug clopidogrel, blunt its activation and reduce antiplatelet protection. Mitigation is monitoring clinical effect, since dose separation does not resolve enzyme competition.
CYP3A4 substrates and inhibitors (ketoconazole, ritonavir, grapefruit juice, simvastatin): Caution; blocking CYP3A4 raised pyranocoumarin blood levels more than tenfold in mice, with unpredictable exposure as the consequence. Mitigation is avoiding strong inhibitors or lowering the herb dose.
CYP2A6 substrates (nicotine, coumarin, letrozole): Caution; decursinol angelate irreversibly inactivates CYP2A6, so nicotine clearance may slow and levels rise. Mitigation is a several-day gap, since the effect persists until new enzyme is synthesized.
Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin): Caution; root coumarins inhibit platelet aggregation in vitro, with bruising and bleeding as the consequence. Mitigation is an international normalized ratio check two weeks after starting or stopping on warfarin.
Over-the-counter analgesics and supplements (ibuprofen, naproxen, aspirin, fish oil, ginkgo, garlic, vitamin E): Caution; each adds antiplatelet or gastric-irritant effect, raising bleeding and stomach-discomfort risk. Mitigation is staggering doses by four hours and keeping the analgesic dose low.
Lipid-lowering agents and lipid-active supplements (fenofibrate, high-dose niacin, omega-3 concentrates, red yeast rice): Caution; additive triglyceride lowering is expected. Mitigation is a lipid panel at twelve weeks rather than untested combination, with liver enzymes added alongside red yeast rice.
Hormonal therapies (estrogen replacement, tamoxifen, androgen-deprivation therapy, finasteride): Caution; the root’s compounds act on both androgen and estrogen receptors in opposing directions, so interference is unpredictable. Mitigation is monitoring the hormone-driven marker the therapy targets.
Other interventions (photodynamic therapy, ultraviolet phototherapy, intense sun exposure, elective surgery): Caution; furocoumarin content can amplify ultraviolet skin injury and platelet inhibition can add surgical bleeding. Mitigation is sun protection and a two-week stop before surgery.

Populations who should avoid Angelica gigas Nakai:

Pregnant or breastfeeding women — no human reproductive safety data exist, and traditional use includes emmenagogue (menstruation-inducing) indications
Adults with active liver disease, or aminotransferase levels above three times the upper reference limit
Adults with a hormone-sensitive cancer — breast, endometrial or prostate — outside a supervised trial, given androgen- and estrogen-receptor activity
Adults with an inherited or acquired bleeding disorder, a platelet count below 100 × 10⁹/L, or surgery scheduled within two weeks
Adults on warfarin or another vitamin-K-antagonist anticoagulant without international normalized ratio monitoring
Children and adolescents under 19 — the lower age bound of every published trial

Risk Mitigation Strategies

Half-dose introduction for two weeks: Beginning at 250 mg of a decursinol-standardized extract once daily rather than twice reduces first-exposure gastrointestinal complaints, the most frequently reported adverse event, before moving to the full daily amount.
Baseline and twelve-week liver panel: Measuring alanine and aspartate aminotransferase before starting and again at twelve weeks catches the within-range enzyme rises documented in trials, and sets the stop threshold at three times the upper reference limit.
Medication review against three enzymes: Screening the current medication list for CYP2C19, CYP3A4 and CYP2A6 substrates before starting addresses the clearest documented risk — pharmacokinetic interaction — since no clinical interaction study exists to fall back on.
Two-week washout before surgery or dental extraction: Stopping at least fourteen days ahead covers the roughly 19-hour parent half-life several times over and removes the theoretical platelet-inhibition contribution to surgical bleeding.
Third-party-tested, species-verified material: Certificates of analysis showing decursin and decursinol angelate content, ochratoxin A below regulatory limits and confirmed species identity prevent both mycotoxin exposure and substitution with Angelica sinensis or Angelica acutiloba.
Daily broad-spectrum sun protection: Because marketed extracts have tested positive for psoralen, xanthotoxin and bergapten, routine sunscreen on exposed skin mitigates the furocoumarin-driven photosensitivity risk, particularly during high-ultraviolet months.

Therapeutic Protocol

Standard practitioner dose: Korean and North American practice converges on 250–500 mg twice daily of a root extract standardized to decursin plus decursinol angelate, or 200 mg daily of the Korean regulator-cleared extract used in the lipid trial.
Competing approach — whole-root decoction: Traditional Korean practice simmers 6–12 g of dried sliced root in water, delivering the water-soluble glycoside nodakenin rather than the ethanol-soluble pyranocoumarins that concentrated capsules supply.
Competing approach — isolated metabolite: A third route standardizes on decursinol alone, on the argument that it is the compound actually circulating; animal work found it outperformed an equal molar dose of the parent pair.
Popularizing sources: The concentrated pain extract is supplied as Decursinol-50 by SunBio Corporation; the memory-positioned extract as Cogni.Q by Quality of Life Labs; the menopause blend as EstroG-100 by Naturalendo Tech.
Best time of day: Trial protocols dosed after breakfast and dinner. Evening dosing suits pain and sleep-related use because decursinol peaks around three hours after intake; morning dosing suits lipid and metabolic use.
Half-life and dose splitting: Parent compounds have roughly 17–19 hour half-lives and decursinol about 7 hours. Twice-daily splitting keeps the short-lived active metabolite present, which is why every published trial used two doses.
Genetic polymorphisms: CYP2C19 status is the pharmacogenetically relevant variant: poor metabolizers reach higher parent-compound exposure and fit the lower end of the range, ultrarapid metabolizers the upper end.
Sex-based differences: Men absorb the parent compounds faster and peak sooner, favoring even dose spacing. No trial has used sex-specific dosing, and the female evidence comes only from combination products.
Age-related considerations: Trials enrolled adults from 19 to 80 without dose adjustment. Adults past 70 with reduced liver clearance are reasonably started at 250 mg once daily and titrated on tolerance rather than on age alone.
Baseline biomarker levels: Fasting triglycerides identify the group with a documented lipid response; the urinary symptom score identifies the group with a documented urinary response. Neither response has been shown outside these baseline states.
Pre-existing health conditions: Symptomatic prostate enlargement, mild hypertriglyceridemia and the menopausal transition are the three states with human outcome data; the protocol above is anchored to those, not to general use.

Discontinuation & Cycling

Intended duration: Every published trial ran twelve weeks or less. Nothing establishes lifelong use; the evidence supports defined twelve-week courses evaluated against a measured endpoint, then continued or stopped on that result.
Withdrawal effects: None have been reported in any trial, in the 13-week rat study, or in post-marketing material. The compounds show no receptor dependence or tolerance profile that would predict a withdrawal syndrome.
Tapering: No taper is described or mechanistically indicated. Abrupt cessation was the design in all human trials, with no rebound in triglycerides, urinary symptoms or menopausal scores reported at follow-up.
Cycling: No cycling schedule has been tested. The open question is whether repeated dosing saturates first-pass conversion, which would change exposure over time; until that is measured, twelve weeks on with reassessment is the conservative default.
Reversal of the enzyme effect: Because CYP2A6 inactivation is mechanism-based, activity returns only as new enzyme protein is made. Interaction risk therefore persists for several days after the last dose, not hours.

Sourcing and Quality

Species verification is the first filter: Three Angelica species are sold as dang-gui with almost no shared marker compounds. Only material identified as Angelica gigas Nakai and showing decursin, decursinol angelate and nodakenin on chromatography carries the studied chemistry.
Standardization target: The clinically studied products are ethanol extracts of the root standardized to pyranocoumarin content; Decursinol-50 is standardized to 0.1% decursinol. Water decoctions and unstandardized powders deliver a materially different compound profile.
Ochratoxin A testing: Field-drying and overloaded thermal drying let ochratoxigenic molds colonize the root. A certificate of analysis showing ochratoxin A below regulatory limits addresses the one contamination risk documented specifically for this crop.
Furocoumarin disclosure: Pharmacopoeial analysis of a marketed supplement detected psoralen, xanthotoxin and bergapten. Suppliers that quantify furocoumarins alongside pyranocoumarins allow the photosensitivity risk to be assessed rather than assumed.
Third-party testing and reputable suppliers: Independent verification of identity, potency, heavy metals and microbial load matters more here than for common supplements. Quality of Life Labs, Naturalendo Tech and Life Extension supply the extracts used in or matched to published trials.
Growing origin and harvest timing: Root pyranocoumarin content varies with cultivation site and harvest year, and only a majority of cultivated samples met the Korean Pharmacopoeia specification, so suppliers increasingly state origin and harvest year on the certificate of analysis.

Practical Considerations

Time to effect: Pain relief in animal models and in the unpublished clinic study appeared within days to two weeks. The lipid, urinary and menopausal endpoints were all measured at twelve weeks, with menopausal scores separating from placebo by week three to six.
Common pitfall — buying the wrong plant: Most products labeled “dong quai” or “dang gui” contain Angelica sinensis, which carries neither decursin nor decursinol angelate. Buying on the common name rather than the binomial defeats the purpose entirely.
Common pitfall — assuming cell-culture potency transfers: Marketing frequently quotes decursin concentrations drawn from laboratory studies that circulating blood levels never approach, because first-pass conversion removes almost all of the parent compound.
Common pitfall — indefinite use without measurement: Every documented benefit is anchored to a measurable baseline. Continuing past twelve weeks without rechecking the relevant marker leaves no way to distinguish response from expense.
Regulatory status: Sold as a dietary supplement in the United States, where claims are not pre-approved; cleared by Korea’s Ministry of Food and Drug Safety as a functional food ingredient for triglycerides; the three-herb menopause blend is capped at 175 mg/day in the European Union.
Cost, access and payer incentives: Standardized extracts run $20–40 monthly, cheaper than the prescription options they might displace. No insurer reimburses them, so payers have no incentive to favor or suppress them, and none funds trials — hence the manufacturer-financed human evidence base.

Interaction with Foundational Habits

Sleep: Indirect and plausibly favorable. Decursin and decursinol angelate promote the enzyme that makes gamma-aminobutyric acid, and animal work reports sedative and anti-anxiety effects. Menopausal trials recorded improved insomnia and sleep-quality scores as secondary outcomes. Evening dosing aligns the roughly three-hour peak of the active metabolite with bedtime.
Nutrition: Direct and dose-relevant. Trial protocols dosed after breakfast and dinner; the pyranocoumarins are fat-soluble, so a meal containing fat aids absorption. Grapefruit and other CYP3A4-inhibiting foods raise exposure unpredictably. No nutrient depletion has been reported in any trial or in the 13-week rodent study.
Exercise: Neutral to indirect. In the lipid trial the extract group reduced physical activity yet still lowered triglycerides, indicating the effect is not exercise-dependent. Nothing suggests blunting of training adaptations; antioxidant-mediated interference with muscle growth has not been examined. No timing requirement around workouts exists.
Stress management: Indirect. Rodent work reports reduced depression-like behavior after chronic corticosterone (the rodent stress hormone) exposure and anxiety reduction through gamma-aminobutyric acid signaling, and the menopause trials recorded improvements in nervousness, tension and stress response. No human cortisol measurement has been published, so the claim rests on animal and questionnaire data.

Monitoring Protocol & Defining Success

Baseline testing establishes which of the three documented response states applies and sets the safety floor. Published protocols record a fasting lipid panel, liver enzymes, a complete blood count with platelets, and kidney function before the first dose, together with the symptom instrument matching the intended use — the urinary symptom score for men with prostate enlargement, the menopause index for women in transition. Success is defined against that baseline, not against a population average.

Ongoing monitoring follows a simple cadence: repeat liver enzymes at 6 weeks, then the full panel with the relevant symptom score at 12 weeks, and thereafter every 6 months if use continues. A twelve-week course that moves neither the biomarker nor the symptom score has failed its own test. Any aminotransferase value above three times the upper reference limit ends the course regardless of symptom benefit.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Fasting triglycerides	<100 mg/dL	The single best-documented benefit	12-hour fast; the conventional cut-off is <150 mg/dL, so the functional target is stricter; trial entry required 130–200 mg/dL
Triglyceride-to-HDL ratio	<2.0	Insulin-resistance and cardiac-risk proxy that moved in the trial	HDL is high-density lipoprotein cholesterol; calculated from the same panel; trial values moved from 3.23 to 2.87
Alanine aminotransferase (ALT)	<25 U/L men, <20 U/L women	Detects the enzyme rises seen in both published trials	ALT is a liver enzyme released when liver cells are stressed; conventional upper limits run to 40–55 U/L; stop above three times the upper limit
Aspartate aminotransferase (AST)	<25 U/L	Pairs with ALT to separate liver from muscle origin	AST is a liver and muscle enzyme; conventional upper limits run to about 40 U/L, so the functional target is stricter; draw with ALT; recent intense exercise raises it independently of the liver
Complete blood count with platelet count	Platelets 150–400 × 10⁹/L	Baseline before any antiplatelet concern	Pair with a personal and family bleeding history; no trial has shown a platelet change on the extract
Prostate-specific antigen (PSA), men over 45	No established target for this use; track change from the individual’s own baseline	The root’s compounds act on androgen-receptor signaling	PSA is a blood marker of prostate activity; draw before digital examination or cycling; the urinary trial found no change
Estradiol and follicle-stimulating hormone (FSH), menopausal use	No established target for this use; track change from the individual’s own baseline	Confirms symptom relief is not occurring through hormonal action	FSH drives ovarian estrogen output; the blend trials found no shift in either, matching non-estrogenic receptor assays
Estimated glomerular filtration rate (eGFR) with urinalysis	>90 mL/min/1.73 m²	Kidney safety floor, relevant to mycotoxin exposure	eGFR estimates how fast the kidneys filter blood; the conventional threshold for normal is ≥60 mL/min/1.73 m², so the functional target is stricter; one trial saw transient urinary protein without other kidney abnormality

Qualitative markers tracked alongside the laboratory values:

Pain intensity and morning joint stiffness, scored 0–10 at the same time each day
Sleep onset time and number of night wakings
Hot flash frequency and intensity for menopausal use
Nocturia episodes (waking at night to urinate) and the sense of complete bladder emptying
Energy through the afternoon and subjective mental clarity
Any new bruising, nosebleed or gum bleeding
Skin reaction after sun exposure

Emerging Research

Prostate trial of a standardized extract: NCT06600698 is a recruiting phase 1/2 study at Penn State Hershey enrolling 45 men with rising prostate-specific antigen, testing dose-limiting toxicity, maximum tolerated dose and antigen change over six cycles — the first efficacy trial of this herb in an oncology setting.
Dose-response safety in patients: NCT05375539 completed a 12-participant phase 1 study of acute dosing in prostate cancer patients, with cardiac electrical safety and blood chemistry as primary endpoints, establishing the exposure range the larger trial now uses.
Human immune-cell effects: NCT03630328 completed a 15-participant placebo-controlled study measuring neutrophil and natural killer cell counts in blood, the only registered attempt to test the immune claims in people. No results have been published.
Blood-flow endpoints: NCT04389125 registered an 80-participant placebo-controlled trial of a root and onion extract mixture with platelet function and blood viscosity as primary outcomes — the study that would confirm or refute the antiplatelet signal. Its status is listed as unknown.
Glucose control: NCT03258229 completed a 40-participant placebo-controlled study of glucose response during an oral glucose tolerance test. No publication has followed, which is itself informative about the likely direction of the result.
Research that could weaken the case: Repeat-dose pharmacokinetics is the pivotal unknown. Lü et al., 2025 flag that a metabolic ceiling or adaptation after repeated use could mean sustained exposure never reaches the concentrations animal efficacy required, undercutting most preclinical extrapolation.
Research that could strengthen the case: Lü et al., 2025 report Rho-associated protein kinases (enzymes controlling cell shape and blood-vessel tone) as new targets of decursinol angelate; with confirmed acetylcholinesterase inhibition, that gives testable mechanisms carrying existing clinical readouts in vascular and cognitive medicine.
Interaction studies are absent: No registered trial pairs the extract with a probe drug for CYP2C19, CYP3A4 or CYP2A6. Until one runs, the interaction section of every review of this herb — including this one — rests on microsomal work rather than clinical measurement.

Conclusion

Angelica gigas Nakai is the Korean member of a group of plants that share a trade name but not their chemistry. Its root carries a distinctive pair of aromatic compounds that the liver converts almost entirely, within a few hours of swallowing, into a single circulating substance, which separates most of the laboratory literature from what actually reaches human tissue.

In people, the measured effects are narrow. A standardized root extract lowered blood fat levels in adults whose levels were mildly raised. A two-herb product eased urinary symptoms in older men, and a three-herb blend containing the root reduced menopausal complaints across several trials. Everything else — memory, tumor suppression, immune signaling, bone, circulation — rests on animals and cell cultures, where the findings are abundant and consistent but untested in humans.

Side effects across the completed trials were no more common than on placebo, with mild digestive complaints and small, within-range rises in liver enzymes. The compounds block liver enzymes that clear many medicines, which is the clearest practical caution and the one gap no trial has yet filled.

Almost every human trial was funded or supplied by the company selling the product, the joint-pain study most often quoted by sellers was never published, and the most detailed consumer article on the herb comes from a company that sells the extract. That funding pattern does not make the findings wrong, but the human evidence has never been tested by a group with nothing to gain.

Top - Benefits - Risks - Protocol

Angelica gigas Nakai for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Relief of Menopausal Symptoms (as Part of a Standardized Three-Herb Extract)

Medium 🟩 🟩

Lower Fasting Triglycerides

Improved Lower Urinary Tract Symptoms (with Astragalus)

Reduced Crow’s-Feet Wrinkles from Topical Root Extract

Low 🟩

Relief of Chronic Degenerative Joint Pain

Speculative 🟨

Memory and Cognitive Support

Tumor Growth and Metastasis Inhibition

Anti-Inflammatory and Immune Modulation

Platelet Inhibition and Blood-Flow Support ⚠️ Conflicted

Bone Preservation

Female Fertility and Embryo Implantation

Anxiety and Sleep Effects

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Gastrointestinal and Nonspecific Adverse Events

Medium 🟥 🟥

Transient Liver-Enzyme Elevation

Low 🟥

Drug-Interaction Potential Through Liver Enzyme Inhibition

Speculative 🟨

Bleeding Risk from Platelet Inhibition ⚠️ Conflicted

Photosensitivity from Furocoumarin Content

Effects on Hormone-Sensitive Tissue

Mycotoxin Contamination of Root Material

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion